Figure S1




Fig S1. MDA PCa PDX-derived organoids. A. Representative H&E images of organoids derived from MDA PCa PDX. **B.** Representative bright field images monitoring organoids derived from MDA PCa 250-15 growth overtime (days 0, 2, 4, 6, 8, 10). **C.** Bright field (BF) and fluorescence images of PDX-derived organoids (118b, 173-2, 352-8) genetically engineered to express Green Fluorescent Protein (GFP). **D.** H&E and AR expression by IHC in MDA PCa 173-2 treated with vehicle (DMSO) or antiandrogen Bicalutamide 100 mM at 48 hours, or untreated (Ctrl). **E.** Cell viability assay of MDA PCa 183-A organoids treated with a range of doses of Cisplatin, Paclitaxel, Cabazitaxel, Bicalutamide (Casodex), Enzalutamide, Niraparib for 96 hours. * P<0.05; ** P<0.01; *** P<0.001. ETOH: ethanol; DMSO: dimethyl sulfoxide.